Mark Goodman
SVP Layering
Replay available
Aldeyra Therapeutics, Inc. (ALDX) Q4 2021 Earnings Call
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) Q4 2021 earnings conference call, held 2022-03-17. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Joshua Reid
Chief Financial Officer
Yagao Nachomovitz
Analyst at Citigroup
Dr. Todd Brady
President and Chief Executive Officer
Thomas Schrader
Analyst at BTIG
Yale Jen
Analyst at Lazel and Company
Matthew Cross
Analyst at Alliance Global Partners
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Aldeyra Therapeutics, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.069 -- 00:00:05.052 Ladies and gentlemen, thank you for standing by, and welcome to the Aldera Therapeutics 00:00:05.052 -- 00:00:08.814 Full Year 2021 Financial Results Conference Call. 00:00:08.814 -- 00:00:12.957 At this time, all participants are in a listen-only mode. 00:00:12.957 -- 00:00:17.440 After the speakers' presentations, there will be a question-and-answer session. 00:00:17.440 -- 00:00:21.582 I would now like to hand over the conference to the company's Chief Financial Officer, 00:00:21.582 -- 00:00:25.764 Mr. Joshua Reid. Please go ahead, sir. 00:00:26.505 -- 00:00:31.618 Good morning, everyone. With me is Dr. Todd Brady, President and Chief Executive Officer 00:00:31.618 -- 00:00:36.781 of Aldera. This morning, we issued a press release reporting our financial results for 00:00:36.781 -- 00:00:39.551 the year end of December 31, 2021. 00:00:40.282 -- 00:00:45.164 A copy of the press release is available on the Investors and Media section of our website, 00:00:45.164 -- 00:00:47.164 www.aldera.com. 00:00:48.946 -- 00:00:52.668 Please note that this morning's conference call contains forward-looking statements regarding 00:00:52.668 -- 00:00:56.209 future events and the future performance of Aldera. 00:00:56.209 -- 00:01:01.417 Forward-looking statements include but are not limited to statements regarding 00:01:01.417 -- 00:01:06.581 submission of potential new drug applications, potential commercialization, the anticipated 00:01:06.581 -- 00:01:12.046 timing of results from our clinical trials, our projected cash runway, our possible 00:01:12.046 -- 00:01:17.471 or assumed future results of operations, expenses and financial position, and potential 00:01:17.471 -- 00:01:19.771 growth opportunities. 00:01:20.013 -- 00:01:24.156 These s...